Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial

Journal article

Cappuccini F. et al, (2020), Journal for ImmunoTherapy of Cancer, 8, e000928 - e000928

5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy

Journal article

Cappuccini F. et al, (2017), Oncotarget, 8, 47474 - 47489

The Human Vaccines Project: A roadmap for cancer vaccine development

Journal article

Romero P. et al, (2016), Science Translational Medicine, 8

Identification and functional validation of MHC Class I epitopes in the tumour-associated antigen 5T4

Journal article

Shingler WH. et al, (2005), IMMUNOLOGY, 116, 34 - 34

Monitoring of Human Immunological Responses to Vaccinia Virus

Journal article

Harrop R. et al, (2004), 243 - 265

Pre-existing immunity to vaccinia virus does not affect efficacy of a recombinant MVX vaccine: Poxvirus cross-reactivity

Conference paper


Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins for Human CD4 + T-Helper 1 Responses

Journal article

Leen A. et al, (2001), Journal of Virology, 75, 8649 - 8659

Accessing Epstein-Barr virus-specific T-cell memory with peptide-loaded dendritic cells.

Journal article

Redchenko IV. and Rickinson AB., (1999), Journal of virology, 73, 334 - 342

CD4+ T cells inhibit growth of Epstein-Barr virus-transformed B cells through CD95-CD95 ligand-mediated apoptosis

Journal article

Wilson A., (1998), International Immunology, 10, 1149 - 1157

Inhibitory effect of calf fetuin on the cytotoxic activity of LAK cell-derived factors and tumor necrosis factor

Journal article

Chertov OY. et al, (1994), Immunology Letters, 42, 97 - 100

Load More